| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9951291 | European Journal of Vascular and Endovascular Surgery | 2005 | 9 Pages |
Abstract
In patients on ASA treatment, long-term postoperative dalteparin treatment did not improve patency after peripheral artery bypass grafting. Therefore, low molecular weight heparin treatment cannot be recommended for routine use after bypass surgery for critical lower limb ischemia.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
L. JivegÃ¥rd, C. Drott, J. Gelin, O. Groth, M. Hensäter, N. Jensen, G. Johansson, P. Konrad, B. Lindberg, A. Lindhagen, B. Lundqvist, A. Oden, L. Smith, B. Stenberg, E. Thornell, U. Wingren, P. Ãrtenwall,